Last updated: February 20, 2026
What is the Drug NDC 70677-0153?
NDC 70677-0153 refers to Gvoke Pre-Filled Syringe, a prescription medication used for emergency treatment of severe hypoglycemia in diabetic patients. Manufactured by Xeris Pharmaceuticals, it is a glucagon injection designed for subcutaneous administration.
Market Overview
Market Size and Growth
The global hypoglycemia treatment market is projected to reach $2.5 billion by 2027, rising at a compound annual growth rate (CAGR) of 7% from 2020 (source: Fortune Business Insights). The key drivers include increasing diabetes prevalence, rising awareness, and technological advancements in emergency treatments.
Patient Population
- Diabetes prevalence in the U.S. (CDC, 2022): Approximately 37.3 million Americans have diabetes; nearly 5-8% experience severe hypoglycemia annually.
- Emergency use potential: Conservatively, 10-15% of severe hypoglycemia episodes in diabetic patients may require glucagon administration, representing a sizable treatment segment.
Competitive Landscape
Major competitors:
- Glucagon Emergency Kit (Eli Lilly)
- Gvoke (Xeris Pharmaceuticals)
- Baqsimi (Eli Lilly, nasal glucagon)
Market differentiation factors include ease of administration, stability, and patient preference.
Regulatory Status
- FDA Approval: Gvoke received FDA approval on May 18, 2019.
- Market penetration: Initial deployment has increased in hospitals, emergency responders, and some pharmacy chains.
Pricing Analysis
Current Price Point
- Gvoke Pre-Filled Syringe: Approximate wholesale acquisition cost (WAC) is $290–$310 per syringe.
- Patient out-of-pocket: Varies from $15 to $60 with insurance, with patient assistance programs offsetting costs.
Price Comparison
| Drug |
Price (WAC) |
Administration Method |
Notes |
| Gvoke Pre-Filled Syringe |
$300 |
Subcutaneous injection |
Single-dose, stable at room temp |
| Eli Lilly Glucagon Emergency Kit |
$220 |
Powder, reconstitution required |
Fewer units in kit, complex prep |
| Baqsimi (nasal) |
$250 |
Nasal spray |
Alternative for needle-phobic patients |
Price Trends
- The initial launch price was approximately $290–$310.
- Recent market dynamics show slight discounts and promotions.
- Generic or biosimilar glucagon products are not widely available, consolidating pricing power for branded formulations.
Future Price Projections
Factors influencing prices:
- Market penetration: Greater adoption could stabilize prices.
- Manufacturing costs: Expected to decrease with scale and technological innovation.
- Competitor entry: Patent expiry or new biosimilars might drive price reductions.
Projected price range over 3 years:
| Year |
Estimated WAC Price |
Drivers |
| 2023 |
$300 |
Steady market share, limited competition |
| 2024 |
$290–$310 |
Increased competition or biosimilars? |
| 2025 |
$270–$300 |
Patent cliffs, generics introductions? |
Market Entry and Pricing Strategies
- Pricing flexibility: Manufacturers should consider patient assistance programs to enhance access.
- Market positioning: Emphasizing convenience, stability, and non-requirement of reconstitution can justify premium pricing.
- Reimbursement: Negotiating with payers and providers remains critical for expanding coverage and ensuring competitive pricing.
Key Takeaways
- The drug is positioned within a growing emergency hypoglycemia treatment segment.
- Price currently ranges around $290–$310 WAC, with patient costs lower through assistance.
- Competition from nasal formulations and existing kits influences pricing, but limited biosimilar activity favors stability.
- Long-term pricing depends on market penetration, competition, and therapeutic positioning.
FAQs
1. What are the main advantages of Gvoke Pre-Filled Syringe over traditional glucagon kits?
It offers ease of use, room temperature stability, and no reconstitution, reducing administration errors during emergencies.
2. How does pricing compare between Gvoke and nasal glucagon products?
Gvoke's WAC is slightly higher than nasal glucagon ($250), but advantages in administration and stability could justify the premium.
3. Are biosimilars expected in the near future?
Currently, no biosimilar glucagon products are approved, but patent expiry could open market entry opportunities in 3–5 years.
4. How does insurance reimbursement affect patient costs?
Coverage varies; patients often pay $15–$60 out of pocket, depending on insurance plans and assistance programs.
5. What factors could lower Gvoke's price in the coming years?
Introduction of biosimilars, increased market competition, and manufacturing efficiencies could reduce prices.
References
- CDC (2022). National Diabetes Statistics Report. Centers for Disease Control and Prevention.
- Fortune Business Insights (2022). Hypoglycemia Treatment Market Size, Share & Industry Analysis.
- FDA (2019). FDA approves Gvoke to treat severe hypoglycemia. U.S. Food and Drug Administration.
- Manufacturer websites and recent pricing data (2023). Accessed March 2023.
